Quaratino is an immunologist and joins Kymab from Novartis, where she has served as Global Clinical Program Leader – Transitional Clinical Oncology, responsible for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology. Prior to her role with Novartis, Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono. She also has over 20 years of professional experience in biomedical research in UK academic institutions including Imperial College London and the University of Southampton.